|
Paul Goddard, Ph.D. has served as Chairman of the board of directors since November 2000. Dr. Goddard has been Chief Executive Officer for ARYx Therapeutics, Inc. since 2005 and Chairman of the Board since 2003. He has also been a director of Adolor, Inc., since 2000 and of Onyx Pharmaceuticals, Inc. since 1997. From 1998 to 2000, Dr. Goddard was President and Chief Executive Officer of Elan's pharmaceutical division. From 1991 to 1998, Dr. Goddard served as Chairman and Chief Executive Officer of Neurex Corporation. In 1998, Neurex was acquired by Elan. Prior to Neurex, Dr. Goddard held various senior management positions at SmithKline Beecham.
Kevin Tang has served as a member of our board of directors since February 2009. Mr. Tang is the Managing Director of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Tang Capital Management holds a significant ownership position in A.P. Pharma’s common stock. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex. Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. He currently serves as a director of Ardea Biosciences, Inc. and Penwest Pharmaceuticals, as well as two private companies, RadPharm, Inc., and Prospect Therapeutics, Inc. Mr. Tang received a BS degree from Duke University.
Gregory Turnbull has served as a member of our board of directors since February 1986 and was President and Chief Executive Officer of the Company from October 2006 until the hiring of Mr. Prentki in July 2008. He was also named interim Chief Financial Officer in January 2008, a position he held until February 2009. Mr. Turnbull has been a private investor and business consultant for over five years. Previously, he was a general partner of Cable & Howse Ventures, a venture capital firm, and also served as an investment banker with Morgan Stanley & Co. and White, Weld & Co. Mr. Turnbull also serves as Chairman of the Board for Planar Systems, Inc. and as a director of certain privately-held companies.
John Whelan joined A.P. Pharma in February 2009 as Vice President, Finance and Chief Financial Officer and was appointed President, Chief Executive Officer and Director in May 2011. Prior to joining us, he was Chief Operating Officer and Chief Financial Officer at Raven biotechnologies, where he oversaw the finance function as well as having broad operational responsibilities. Mr. Whelan also held the position of Vice President and Chief Financial Officer at Eos Biotechnology, where he was responsible for finance, business development, and administration. Previously, Mr. Whelan held a number of management positions at Hewlett Packard/Agilent, culminating in his tenure as Director of Corporate Development, during which he led the consummation of numerous acquisitions, investments, and collaborations with companies in the life sciences, medical devices, and computing industries. Mr. Whelan has a BS in Engineering from the University of California, Berkeley and an MBA from the Anderson Graduate School of Management at UCLA.
|
 |
